InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,532.00
(
0.64%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.78
(
0.09%
)
Bitcoin
66,319.72
(
2.08%
)
Post# of 252255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: JohnWayne post# 151892

Wednesday, 11/07/2012 3:35:21 PM

Wednesday, November 07, 2012 3:35:21 PM

Post# of 252255

Novartis has guided in recent calls that the base patent (I would presume the composition of matter patent, but I haven't really looked into it) for Gleevec expires in the US in late 2015.

Correct, the COM patent #5521184 runs until July 2015 (including pediatric exclusivity).

However, they also have a variety of patents on other isoforms/polymorphs/crstalline formulations that they will try to use to defend against generics beyond the base patent expiry.

These are patents #7544799 and #6894051, beta crystal form of Gleevec expiring in 2019. I think Sun Pharma attacked those patents and they got a tentative approval for generic Gleevec from the FDA.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up